Pharmaceutical formulation containing gelling agent
AssigneesPurdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
InventorsCurtis Wright, Benjamin Oshlack, Christopher Breder
Life of this patent
Estimating the term…
Abstract
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Claims1
An extended release abuse deterrent dosage form comprising:
- a. a core matrix comprising a blended mixture of:
- (a) PEO having a molecular weight of from about 300,000 daltons to about 5,000,000 daltons;
- (b) magnesium stearate;
- and
- (c) oxycodone or a pharmaceutically acceptable salt thereof;
- wherein the core matrix is heated to melt at least a portion of the PEO included in the core matrix during preparation of the dosage form;
- and
- b. PEG applied onto the core matrix;
- wherein the dosage form provides extended release of the drug.
Dependencies are inferred from the claim text.